News

Markers of Acute Kidney Injury to be Monitored in Forthcoming Clinical Trials BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) February 27, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function announced that it has expanded its clinical advisory board to include John Kellum, MD–noted critical care physician […]

New Patents Issued Across Multiple Geographies in US, Japan and Canada BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2016) BioAegis Therapeutics announces that during 2016 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infectious disease, neurological disease and renal failure. The plasma gelsolin portfolio now includes

BioAegis Therapeutics announced that it has completed two successful manufacturing runs to produce lyophilized clinical supplies of plasma gelsolin. The drug product in this formulation has already been found to be highly temperature-stable in over two years of stability studies, which are ongoing. The lypophilization of biologics is utilized to eliminate the necessity of cold-chain

National Institute of Allergy and Infectious Diseases awarded a 3-year $ 2.8 million grant to a partnership between BioAegis and TH Chan Harvard School of Public Health researchers. The grant will advance the study of pGSN replacement as a therapy for antibiotic-resistant pneumonia. The highly competitive R01 grant was responsive to a Request for Applications

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 22, 2016 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN) won Best Presentation Award at the CM-Equity Conference in Munich, Germany.  Presenting for the company was Mr. Steven Cordovano, Co-Founder and Vice President of Investor Relations. CM-Equity is a diversified financial services firm

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has sold a combination of net operating losses and R&D Credits totaling $544,000. The company’s application to this State of New Jersey’s Technology Business Tax Credit Transfer Program was previously accepted in June.

Company Develops Temperature-Stable Lyophilized Protein BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has successfully completed development of a lyophilized form of plasma gelsolin. Lyophilization is the process of converting the bulk drug substance into a freeze-dried form that can be stored in vials at room temperature.

Patents Granted for Renal Failure in Japan and Inflammation in Korea BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – September, 2015) BioAegis Therapeutics announced today patents were recently granted covering plasma gelsolin uses for renal failure in Japan and inflammation in Korea. Further applications in jurisdictions in Asia are also pending.

NIAID Anticipates Funding Host-Based Approaches to Antimicrobial Resistance BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 15, 2015) BioAegis Therapeutics announces that it has met with representatives from The National Institute of Allergy and Infectious Diseases (NIAID) and The Biomedical Advanced Research Development Agency (BARDA) to discuss plasma gelsolin’s role in in combatting antibiotic

Despite rigorous, contemporary methodology, pathogens are not identified in the majority of CAP cases. In addition, viruses play a role greater than previously recognized and were detected almost twice as frequently as bacteria. This study indicates a need for a host-based approach which does not depend on a specific pathogen, such as BioAegis’ plasma gelsolin